Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

As an update to data reported at the EORTC-NCI-AACR (ENA) conference in October 2024, the company shared a new analysis of safety and activity data from the July 23, 2024 data cutoff date in patients ...

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...

Explore how E-selectin-targeted polymer-doxorubicin therapy induces regression in colorectal liver metastases.

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

Cancer metabolism is a critical area of research, central to understanding how malignant tumors manipulate metabolic pathways to support their growth and survival. These alterations not only fuel ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...